Park Square has placed Stephen Basso as Chief Financial Officer at Cybrexa Therapeutics.
| less than a minute read
Cybrexa Therapeutics Appoints Stephen Basso as Chief Financial Officer
Get in touch
Get in touch
Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has appointed pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer.
Get in touch
Get in touch
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-29-16-59-13-899-6abbee61460fb9469a25b973.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-10-21-12-53-31-969-6ad8b5cb057433a11d528afb.jpg)
/Passle/58a5cb8db00e8110e83aa395/SearchServiceImages/2026-10-19-20-59-27-876-6ad684af780cfbe7accbf179.jpg)
